Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.530
+0.020 (0.57%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Fulcrum Therapeutics stock have an average target of 6.57, with a low estimate of 2.00 and a high estimate of 15. The average target predicts an increase of 86.12% from the current stock price of 3.53.
Analyst Consensus: Hold
* Price targets were last updated on Feb 26, 2025.
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 6 | 6 | 6 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 10 | 10 | 9 | 9 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +13.31% | Feb 26, 2025 |
RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +13.31% | Nov 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | +13.31% | Nov 14, 2024 |
RBC Capital | RBC Capital | Buy → Hold Downgrades $15 → $4 | Buy → Hold | Downgrades | $15 → $4 | +13.31% | Sep 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $17 → $4 | Strong Buy → Hold | Downgrades | $17 → $4 | +13.31% | Sep 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 80.00M
Revenue Next Year
20.75M
EPS This Year
-1.22
from -0.16
EPS Next Year
-1.30
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 83.8M | n/a | ||
Avg | n/a | 20.7M | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.09 | -1.17 | -1.20 | ||
Avg | -1.22 | -1.30 | -1.27 | ||
Low | -1.35 | -1.35 | -1.32 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.